A mathematical model for cancer treatment based on combination of anti-angiogenic and immune cell therapies

被引:6
|
作者
Nave, OPhir [1 ]
Sigron, Moria [1 ]
机构
[1] Jerusalem Coll Technol, Dept Math, Jerusalem, Israel
关键词
Mathematical model; Stability analysis; VEGF; Anti-VEGF; Cancer treatment; Angiogenic; Tumor vasculature; KINETICS; PERTURBATION; INJECTION; HUMANS;
D O I
10.1016/j.rinam.2022.100330
中图分类号
O29 [应用数学];
学科分类号
070104 ;
摘要
In this study, we investigated a mathematical model that integrated mechanisms of tumor angiogenesis and tumor-targeted cytotoxicity in immune cells. The model considered the interaction of cancer cells with the immune system and the treatment that combines unlicensed dendritic cells and anti-vascular endothelial growth factor antibodies. We proposed an unconventional treatment protocol; for now, treatment is purely theoretical and has not been practically attempted. The treatment has been described by analytical functions that depend on time and dose. This was a function of t and q, where q is the amount (dose) of the drug. A customized treatment is a significant advantage of explicit analytical functions. We compared the results obtained from the mathematical model with the proposed treatment to the clinical results and observed an almost complete match between the treatments. In addition, we applied the global quasi-linearization GQL method to the mathematical model, which enabled us to expose the hierarchy of the system and, hence, split the system into fast and slow subsystems. This decomposition enabled us to analytically compute the equilibrium points of the model and their stability, which is crucial for the application. (c) 2022 Published by Elsevier B.V.
引用
收藏
页数:23
相关论文
共 50 条
  • [1] A cancer treatment based on synergy between anti-angiogenic and immune cell therapies
    Soto-Ortiz, Luis F.
    CANCER RESEARCH, 2016, 76
  • [2] A cancer treatment based on synergy between anti-angiogenic and immune cell therapies
    Soto-Ortiz, Luis
    Finley, Stacey D.
    JOURNAL OF THEORETICAL BIOLOGY, 2016, 394 : 197 - 211
  • [3] In pursuit of new anti-angiogenic therapies for cancer treatment
    Cai, Jun
    Han, Song
    Qing, Ruan
    Liao, Daiqing
    Law, Brian
    Boulton, Michael E.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2011, 16 : 803 - 814
  • [4] A FRACTIONAL-ORDER DELAY DIFFERENTIAL MODEL WITH OPTIMAL CONTROL FOR CANCER TREATMENT BASED ON SYNERGY BETWEEN ANTI-ANGIOGENIC AND IMMUNE CELL THERAPIES
    Sweilam, Nasser
    Rihan, Fathalla
    Al-Mekhlafi, Seham
    DISCRETE AND CONTINUOUS DYNAMICAL SYSTEMS-SERIES S, 2020, 13 (09): : 2403 - 2424
  • [5] Anti-angiogenic therapies for gastric cancer
    Hironaka, Shuichi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (04) : 208 - 217
  • [6] Anti-angiogenic therapies in prostate cancer
    Maria Martinez-Jabaloyas, Jose
    Antonio March-Villalba, Jose
    Mercedes Navarro-Garcia, Maria
    Dasi, Francisco
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (01) : 1 - 5
  • [7] Anti-Angiogenic Therapies for Children with Cancer
    Andre, N.
    Verschuur, A.
    Rossler, J.
    Sterba, J.
    CURRENT CANCER DRUG TARGETS, 2010, 10 (08) : 879 - 889
  • [8] A mathematical model for the effect of anti-angiogenic therapy in the treatment of cancer tumours by chemotherapy
    Pinho, S. T. R.
    Bacelar, F. S.
    Andrade, R. F. S.
    Freedman, H. I.
    NONLINEAR ANALYSIS-REAL WORLD APPLICATIONS, 2013, 14 (01) : 815 - 828
  • [9] Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
    Song, Yuxiao
    Fu, Yang
    Xie, Qi
    Zhu, Bo
    Wang, Jun
    Zhang, Bicheng
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [10] Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
    Haibe, Yolla
    Kreidieh, Malek
    El Hajj, Hiba
    Khalifeh, Ibrahim
    Mukherji, Deborah
    Temraz, Sally
    Shamseddine, Ali
    FRONTIERS IN ONCOLOGY, 2020, 10